Clinical trials: Anaplastic Astrocytoma
Advanced Cancer, Ovarian Cancer
3D Prediction of Patient-Specific Response
This is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or resected tumor tissue for assessing tissue response to…
- Conditions
- Advanced Cancer, Ovarian Cancer, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Trial name
- 3D-PREDICT (NCT03561207)
- Testing
- EV3D Assay
- Where
- 9 sites in United States
- Volunteers
- 570 people
- Sponsor
- KIYATEC
Glioblastoma, Anaplastic Astrocytoma
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
This is a multicenter, open-label, ascending-dose trial of the safety and tolerability of increasing doses of Toca 511, a Retroviral Replicating Vector (RRV), administered to patients with recurrent high grade glioma (rHGG) who…
- Conditions
- Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01156584
- Testing
- Toca 511 vector, Toca FC
- Where
- 10 sites in United States
- Volunteers
- 54 people
- Sponsor
- Tocagen Inc.
High Grade Glioma, Astrocytoma
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
- Trial name
- NCT06161974
- Testing
- Olutasidenib + TMZ
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Rigel Pharmaceuticals